Form 4: Quest Diagnostics CEO Sells Shares After Option Exercise

Quest Diagnostics CEO and President J. E. Davis exercised stock options and subsequently sold 55,093 shares of common stock under a pre-arranged Rule 10b5-1 plan.

Summary

• J. E. Davis, CEO and President of Quest Diagnostics Inc. (DGX), exercised 55,093 non-qualified stock options at a price of $95.795 per share on November 25, 2025.
• Concurrently, Davis sold a total of 55,093 shares of Quest Diagnostics common stock on November 25, 2025, through multiple transactions.
• The sales were executed at weighted average prices of $191.5888, $192.2715, and $192.9717 per share.
• All transactions were conducted pursuant to a pre-arranged Rule 10b5-1 sales plan.
• Following these transactions, Davis beneficially owns 120,480 shares of Quest Diagnostics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an executive sold shares, it was part of a pre-arranged plan (Rule 10b5-1), which mitigates negative interpretations. The exercise of options also indicates the executive is realizing value from compensation.

Positives

• The exercise of stock options indicates the executive is realizing value from previously granted equity compensation.
• The transactions were conducted under a Rule 10b5-1 plan, which suggests a pre-planned liquidity event rather than a reaction to new, non-public information.

Negatives

• The sale of shares by a high-ranking executive could be perceived by some investors as a reduction in insider ownership, although it was part of a pre-arranged plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, though the Rule 10b5-1 plan context suggests a planned liquidity event rather than a change in confidence.

Key Dates

Recommendation

The Form 4 filing details a pre-planned insider transaction where the CEO exercised options and sold shares. This is a routine event for executive compensation and liquidity management, not indicative of a change in the company's fundamental outlook. Investors should 'hold' as this transaction alone does not provide new information to warrant a change in investment thesis, but rather confirms an expected executive compensation event.

Keywords

Quest Diagnostics, DGX, J. E. Davis, Insider Trading, Form 4, Stock Options, Share Sale, Rule 10b5-1, CEO, Executive Compensation